Chemours/$CC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Chemours
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, paints and coatings, plastics, transportation, semiconductor, and others. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
- Ticker
- $CC
- Sector
- Materials
- Primary listing
- NYSE
- Employees
- 5,700
- Headquarters
- Wilmington, United States
- Website
- www.chemours.com
Chemours Metrics
BasicAdvanced
$2B
-
-$2.03
1.42
$0.35
2.69%
Price and volume
Market cap
$2B
Beta
1.42
52-week high
$28.67
52-week low
$10.44
Average daily volume
2.1M
Dividend rate
$0.35
Financial strength
Current ratio
1.663
Quick ratio
0.844
Long term debt to equity
-83.938
Total debt to equity
-84.646
Interest coverage (TTM)
0.78%
Profitability
EBITDA (TTM)
533
Gross margin (TTM)
15.40%
Net profit margin (TTM)
-5.24%
Operating margin (TTM)
3.69%
Effective tax rate (TTM)
-510.00%
Revenue per employee (TTM)
$1,020,000
Management effectiveness
Return on assets (TTM)
1.42%
Return on equity (TTM)
-319.37%
Valuation
Price to revenue (TTM)
0.339
Price to book
-40.01
Price to tangible book (TTM)
-20.21
Price to free cash flow (TTM)
9.007
Free cash flow yield (TTM)
11.10%
Free cash flow per share (TTM)
1.447
Dividend yield (TTM)
2.69%
Forward dividend yield
2.69%
Growth
Revenue change (TTM)
-0.91%
Earnings per share change (TTM)
-29.17%
3-year revenue growth (CAGR)
-2.70%
10-year revenue growth (CAGR)
0.48%
3-year earnings per share growth (CAGR)
51.48%
10-year earnings per share growth (CAGR)
16.03%
3-year dividend per share growth (CAGR)
-29.53%
10-year dividend per share growth (CAGR)
14.55%
What the Analysts think about Chemours
Analyst ratings (Buy, Hold, Sell) for Chemours stock.
Analyst projections of the future price of Chemours stock.
Bulls say / Bears say
Titanium Technologies has begun to secure higher prices: Chemours said pricing actions lifted TiO₂ prices by about 5% year to date, helping sales rise 1% in Q2 despite a 2% volume decline. (Chemours)
Cash generation improved sharply, with Q2 free cash flow up 128% year on year to $114 million. Chemours also used cash and land-sale proceeds to repay €230 million of term debt, supporting its deleveraging effort. (Chemours)
Chemours is gaining exposure to higher-growth markets: Q2 sales in APM Performance Solutions grew 8% year on year, with demand strength in data centre and semiconductor applications and progress in liquid-cooling product trials. (Chemours)
The refrigerants business faces a near-term demand hangover: Opteon sales fell 10% year on year in Q2, and Chemours expects TSS sales to decline 15–20% sequentially in Q3 as aftermarket inventories unwind. (Chemours)
Titanium dioxide demand remains weak in key markets: TT volumes fell 2% year on year in Q2, while higher costs offset pricing gains and left its adjusted EBITDA margin at 7%. (Chemours)
Financial flexibility is still constrained: net leverage was 4.4x and stockholders’ equity was negative $49 million at June 30, while Chemours warns that adverse legal or environmental outcomes could materially affect liquidity. Its North Carolina PFAS settlement also brings a further multi-year payment commitment, despite being covered by existing accruals. (SEC, Chemours)
Data summarised monthly by Lightyear AI. Last updated on 25 Oct 2026.
Chemours Financial Performance
Revenues and expenses
Chemours Earnings Performance
Company profitability
Upcoming events
No upcoming events
Chemours News
AllArticlesVideos
Bronstein, Gewirtz & Grossman LLC Urges Chemours Company Investors to Act: Class Action Filed Alleging Investor Harm
Newsfile Corp7 hours ago
CC INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds The Chemours (CC) Investors of Securities Class Action Lawsuit Deadline on December 7, 2026
Newsfile Corp9 hours ago
CC UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds The Chemours Investors of Securities Class Action Lawsuit Deadline on December 7, 2026
Newsfile Corp3 days ago
Funds containing Chemours
AllUSDEURGBP
Fund name | Fund size | $CC weighting |
|---|---|---|
L&G Hydrogen Economy$HTWO | $464M | 2.37% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.11% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.11% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.07% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.